Supplementary Figure 1. VLDL-TG secretion rates 10-h vs. 5-h fasted rats. No differences in the concentrations of plasma TG and rates of appearance of VLDL-TG in plasma during tyloxapol VLDL-TG secretion studies were observed between rats that were fasted for (A) 10 hours or (B) 5 hours.
Supplementary Figure 2. Plasma HDL and LDL/VLDL cholesterol and total bile acid levels.
No differences in plasma (A) HDL or (B) LDL/VLDL cholesterol levels were observed between MBH vehicle- (white squares) or MBH oleate- (black squares) treated rats at t=150 min of tyloxapol VLDL-TG secretion studies. (C) Plasma total bile acids were increased in MBH oleate-treated (black squares) rats at t=150 min of tyloxapol VLDL-TG secretion studies (* P<0.004 vs MBH vehicle).
Supplementary Figure 3. MBH PKC-δ and PKC-ε protein levels in rats injected with Ad-DN PKC-δ or Ad-LacZ into the MBH. (A) Representative blots and relative quantitative levels of (B) MBH PKC-δ levels in rats injected with MBH Ad-LacZ (white squares, n=6) or MBH Ad-DN PKC-δ (black squares, n=6). MBH Ad-DN PKC-δ injection increased MBH PKC-δ levels (* P<0.02 vs MBH Ad-LacZ). (C) Representative blots and relative quantitative levels of (D) MBH PKC-ε levels in rats injected with MBH Ad-LacZ (white squares, n=6) or Ad-DN PKC-δ (black squares, n=6). MBH Ad-DN PKC-δ vs Ad-LacZ injection did not alter MBH PKC-ε levels.
Supplementary Figure 4. Scans of uncropped Western blots. Corresponding to representative images shown in: (A) Figure 1E; (B-D) Figure 2E. (E-K) Figure 2G; (L-M) Supplementary Figure 3C.
Original scans of blots for Figure 2G: proteins as indicated (representative image in dotted red box)